Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class I · High risk Terminated Initiated Jul 12, 2013 (13 years ago)

0.75% Bupivacaine HCl Injection (Bupivacaine Hydrochloride)

Class I — High risk. Reasonable probability of serious harm or death.

Why it was recalled

Presence of particulate matter: visible free floating and partially embedded particulate matter in the glass vials.

Cause type: Particulate / foreign matter

Visible foreign particles - glass, metal, fibers or other material - found in the product. Particles can enter from equipment wear, containers or the process, and are dangerous in injectables. All particulate / foreign matter recalls.

What was recalled

0.75% Bupivacaine HCl Injection, USP, 7.5 mg/mL, 30 mL, Single-dose, Hospira Inc., Lake Forest, IL 60045, NDC 0409-1165-02

Affected NDC 0409-1165-02

Compare with the code on your package — it is the most precise check available.

Drug: Bupivacaine

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Bupivacaine Hydrochloride
NDC 00409-1165
7.5 mg/mL Injection, Solution
Epidural|retrobulbar
Hospira, Inc. Rx
Recalling firm
Hospira Inc.
NDC code
0409-1165-02
Origin
IL, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-381-2014 · FDA notice

Treat this as urgent. Class I means FDA judged there is a reasonable probability of serious harm. Find the lot number on your package; if it matches the recalled lots, do not take another dose before you have spoken to your pharmacist or prescriber - today, not next week. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Bupivacaine recalls

See all

Other recalls by Hospira Inc.

All 2013 recalls
Class II · Moderate risk

DOBUTamine Injection

Discoloration: Firm received complaints of product discoloration and particulates.

Terminated Failed specification Hospira Inc. NDC 0409-2025-20 D-1500-2016